Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456965 | 0.88 | KEAP1 (0.48) | CYP1A2SMN1; SMN2ALDH1A1KDM4EKEAP1 | |
| SCHEMBL4002577 | 0.86 | KEAP1 (0.47) | CYP1A2SMN1; SMN2ALDH1A1KDM4EKEAP1 | |
| Isothiocyanate SCHEMBL22394167 | 0.83 | SMN1; SMN2 (0.44) | CYP1A2SMN1; SMN2ALDH1A1KDM4EKEAP1 | |
| SCHEMBL11586872 | 0.83 | CYP1A2 (0.64) | CYP1A2SMN1; SMN2ALDH1A1KDM4EKEAP1 | |
| SCHEMBL1269251 | 0.80 | LMNA (0.43) | CYP1A2ALDH1A1CA12CA1CA2 | |
| SCHEMBL14376932 | 0.79 | CYP1A2 (0.51) | CYP1A2SMN1; SMN2ALDH1A1KDM4EKEAP1 | |
| SCHEMBL2256760 | 0.79 | CYP1A2 (0.51) | CYP1A2SMN1; SMN2ALDH1A1KDM4EKEAP1 | |
| SCHEMBL2658154 | 0.79 | CYP1A2 (0.51) | CYP1A2SMN1; SMN2ALDH1A1KDM4EKEAP1 | |
| SCHEMBL1268595 | 0.78 | LMNA (0.47) | CYP1A2SMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL15269270 | 0.77 | TRPA1 (0.39) | CYP1A2ALDH1A1KEAP1SIGMAR1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383378-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | claimed |
| EP-3383376-B1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2021-05-12 | — | — | EP | claimed |
| EP-3383376-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| EP-3383378-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| WO-2017095995-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| WO-2017095993-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| CN-105267967-A | Combined application of isothiocyanate-type compound and anti-cancer drug acting or affecting DNA | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2016-01-27 | — | — | CN | claimed |
| CN-104415332-A | Combined application between isothiocyanate-type compound and kinase inhibitor medicine in treatment of cancer | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2015-03-18 | — | — | CN | claimed |
| CN-104117064-A | Combined application of isothiocyanate compound and hormone medicine | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2014-10-29 | — | — | CN | claimed |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| EP-4508048-A1 | INHIBITORS OF INTERACTIONS BETWEEN TRF1-TIN2 OR TRF2-TIN2 TELOMERIC PROTEINS FOR USE IN ANTICANCER THERAPY | Politechnika Gdanska (PL) | 2025-02-19 | — | — | EP | disclosed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
| EP-0283041-A1 | Direct positive silver halide photosensitive material and method for forming direct positive image | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
| EP-0249239-A2 | Process for the formation of direct positive images | FUJI PHOTO FILM CO., LTD. (JP) | 1987-12-16 | — | — | EP | disclosed |
| US-4554242-A | Method for processing color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | CYP1A2 3167/4885SMN1; SMN2 4815/4885ALDH1A1 2081/4885 |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | CYP1A2 4885/4885SMN1; SMN2 1295/4885ALDH1A1 4773/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | CYP1A2 4853/4885SMN1; SMN2 3923/4885ALDH1A1 4802/4885 |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | HNMT, BHMT, PNMT | CYP1A2 1854/4885SMN1; SMN2 2360/4885ALDH1A1 1166/4885 |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | CRAT, CPT1A, CPT1B | CYP1A2 1366/4885SMN1; SMN2 1141/4885ALDH1A1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.